Meeting Highlights| Volume 4, ISSUE 3, P166-172, August 2003

2003 Highlights From: 39th Annual Meeting of the American Society of Clinical Oncology Chicago, Illinois May 31 to June 3, 2003

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kimmick GG
        • Muss HB
        Systemic therapy for older women with breast cancer.
        Oncology (Huntingt). 2001; 15: 280-291
      1. Multi-agent chemotherapy for early breast cancer (Cochrane Review).
        Cochrane Database Syst Rev. 2002;
        • Early Breast Cancer Trialists' Collaborative Group
        Polychemotherapy for early breast cancer: an overview of the randomised trials.
        Lancet. 1998; 352: 930-942
        • Muss H
        • Woolf S
        • Berry D
        • et al.
        Older Women with Node-Positive (N+) Breast Cancer (BC).
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #11).: 4
        • Coleman RE
        Current and future status of adjuvant therapy for breast cancer.
        Cancer. 2003; 97: 880-886
        • Cocconi G
        • Di Blasio B
        • Boni C
        • et al.
        Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
        Cancer. 2002; 95: 228-235
        • Levine MN
        • Bramwell VH
        • Pritchard KI
        • et al.
        Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute Canada Clinical Trials Group.
        J Clin Oncol. 1998; 16: 2651-2658
        • Mouridsen HT
        • Andersen J
        • Andersson M
        • et al.
        Adjuvant Anthracycline in Breast Cancer: Improved Outcome in Premenopausal Patients Following Substitution of Methotrexate in the CMF Combination with Epirubicin.
        Proc Am Soc Clin Oncol. 1999; 18 (Abstract #254).: 68a
        • Poole CJ
        • Earl HM
        • Dunn JA
        • et al.
        NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #13).: 4
        • Nole F
        • Munzone E
        • Orlando L
        • et al.
        First Line Chemotherapy for Metastatic Breast Cancer (MBC): A Regimen with a Low Subjective Toxic Burden Containing Vinorelbine (V), Continuous Infusion 5-fluorouracil (ci FU) and Cisplatin (P) (ViFuP).
        Proc Am Soc Clin Oncol. 1999; 18 (Abstract # 429).: 113a
        • Vogel C
        • Hochster H
        • Blumenreich M
        • et al.
        A US multicenter phase II study of IV Navelbine (NVB) and 5-fluorouracil (5FU) as first line treatment of patients with advanced breast cancer (ABC).
        Proc Am Soc Clin Oncol. 1995; 14 (Abstract #62).: 91
        • Berruti A
        • Sperone P
        • Bottini A
        • et al.
        Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines.
        J Clin Oncol. 2000; 18: 3370-3377
        • Ahn J
        • Kim S
        • Ahn S
        • et al.
        Phase II study of capecitabine and vinorelbine in anthracycline and taxane pretreated breast cancer patients: Final results.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #216).: 54
        • Stuart N
        • Bishop J
        • Johnson SRD
        • et al.
        Vinorelbine and capecitabine (VX) for advanced breast cancer - a phase II study showing good activity and potential for further development.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #183).: 46
        • Welt A
        • von Minckwitz G
        • Borquez D
        • et al.
        Extended phase I study of capecitabine in combination with vinorelbine in pretreated patients with advanced breast cancer.
        Breast Cancer Res and Treat. 2002; (Abstract #336).: 76
        • Ghosn M
        • Farhat F
        • Kattan J
        • et al.
        Final results of a phase II study of vinorelbine in combination with capecitabine as first line chemotherapy for metastatic breast cancer (MBC).
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #270).: 68
        • Von Minckwitz G
        • Raab G
        • Blohmer J
        • et al.
        Primary chemotherapy adapted on in vivo chemosensitivity in patients with primary breast cancer. The pilot GEPARTRIO study.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #85).: 22
        • Milla-Santos A
        • Milla L
        • Rallo L
        • et al.
        Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer.
        Breast Cancer Res Treat. 2001; 65: 119-124
        • Kitchen PR
        • Smith TH
        • Henderson MA
        • et al.
        Tubular carcinoma of the breast: prognosis and response to adjuvant systemic therapy.
        Aust N Z J Surg. 2001; 71: 27-31
        • Pagani O
        • Gelber S
        • Simoncini E
        • et al.
        Randomized comparison of adjuvant toremifene (Tor) versus tamoxifene (Tam) for postmenopausal women with node-positive (N+) estrogen receptor-positive (ER+) early stage breast cancer.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #79).: 20
        • Shibutani S
        • Ravindernath A
        • Terashima I
        • et al.
        Mechanism of lower genotoxicity of toremifene compared with tamoxifen.
        Cancer Res. 2001; 61: 3925-3931
        • Holli K
        • Valavaara R
        • Blanco G
        • et al.
        Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with nodepositive breast cancer. Finnish Breast Cancer Group.
        J Clin Oncol. 2000; 18: 3487-3494
        • Holli K
        Tamoxifen versus toremifene in the adjuvant treatment of breast cancer.
        Eur J Cancer. 2002; 38: S37-S38
        • Miyauchi K
        • Sano M
        • Kimura M
        • et al.
        Effect of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #165).: 41
        • Nordenskjold B
        • Rutqvist L
        • Malmstrom J
        • et al.
        The Swedish Breast Cancer Group trial of two versus five years of adjuvant tamoxifen: disease recurrence, cause-specific mortality and primary malignancies.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #60).: 16
        • Slamon DJ
        • Leyland-Jones B
        • Shak S
        • et al.
        Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
        N Engl J Med. 2001; 344: 783-792
        • Sparano JA
        • Malik U
        • Rajdev L
        • et al.
        Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
        J Clin Oncol. 2001; 19: 3117-3125
        • Wolff A
        • Bonetti M
        • Sparano JA
        • et al.
        Cardiac Safety of Trastuzumab (H) in Combination with Pegylated Liposomal Doxorubicin (D) and Docetaxel (T) in HER2-Positive Metastatic Breast Cancer (MBC): Preliminary Results of ECOG 3198.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #70).: 18